Unique Features of a Comprehensive Genomic Profiling Panel - Expanding Treatment Options in a Value-Based Community Oncology Network - Original Reports - Precision Medicine

Sep 23, 2026

Comprehensive genomic profiling (CGP) is recommended to tailor precision-guided cancer therapies, yet existing guidance often does not specify which panel features and sizes matter most. This pilot pan-cancer study evaluated patients treated in a value-based community oncology setting who received NGS-based CGP and expanded analyses of de-identified records. Potentially actionable alterations were identified more often with advanced features than with standard in-network testing.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Abstract

Purpose

Materials and Methods

Results

Conclusion

Introduction

Clinical and Knowledge Context

Objective and Key Knowledge Generated

Context

Key Objective

Knowledge Generated

Relevance

Original Reports | Precision Medicine Unique Features of a Comprehensive Genomic Proﬁling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network Paul La Porte, MD, PhD1; Arya Ashok, PhD2 ; Nathan W. Sweeney, PhD2 ; Dana F. DeSantis, PhD2 ; Calvin Chao, MD2,3 ; Omkar Marathe, MD4; and Ezra E.W. Cohen, MD2 DOI [https://doi.org/10.1200/PO-25-00623](https://doi.org/10.1200/PO-25-00623) | ABSTRACT | | | --- | --- | | PURPOSE | Comprehensive genomic proﬁling (CGP) is strongly advocated by organizations like ASCO and National Comprehensive Cancer Network (NCCN) to tailor precision-guided therapies for patients with cancer. However, these guidelines often lack speciﬁcity regarding panel size or essential features required within CGP panels. | | MATERIALS
AND METHODS | A pilot pan-cancer study of patients (N 5 85) treated in a value-based community health care setting who received next-generation sequencing (NGS)– based CGP from Tempus AI, Inc and an expanded analysis of de-identiﬁed patient records from the Tempus database (N 5 465) for patients treated within a community health care network. Rates of potentially actionable ﬁndings deﬁned as variants matching US Food and Drug Administration –approved therapies (somatic variants/resistance markers, Tumor Mutational Burden high [TMB-H] or Microsatellite Instability high [MSI-H]), or identiﬁcation of pathogenic/likely pathogenic germline ﬁndings. Enrollment in clinical trials was included in the expanded cohort. | | RESULTS | In our pilot cohort, potentially actionable alterations were detected in 49% of patients (n 5 42) . Of them, 12%(n 5 5) of patients had a ﬁnding that wasidentiﬁed only by advanced features—including tumor-normal match, RNA sequencing, and/or liquid biopsy reﬂex testing—and may have been missed by the existing in-network NGS options. In the expanded cohort, potentially actionable alterations were detected in 31%(n 5 146) of patients. Of them, 12%(n 5 17) had ﬁndings identiﬁed solely by advanced features, including three patients enrolled in clinical trials. | | CONCLUSION | This study indicates that the CGP expanded treatment options in both the pilot and expanded cohort, with improvements directly attributable to speciﬁc features like tumor-normal matching, liquid biopsy reﬂex ordering, RNA sequencing, and Just-in-Time clinical trial matching. | ACCOMPANYING CONTENT Appendix Accepted January 22, 2026 Published March 9, 2026 JCO Precis Oncol 10:e2500623 © 2026 by American Society of Clinical Oncology Creative Commons Attribution Non-Commercial No Derivatives 4.0 License INTRODUCTION ASCO issued a provisional clinical opinion in 2022 recommending that patients with metastatic and advanced cancer receive next-generation sequencing (NGS) testing when the cancer type has one or more genomic biomarkers linked to an US Food and Drug Administration (FDA)–approved therapy.1 However, while advocating for NGS testing, the opinion refrained from providing explicit guidance on details such asthe composition of the NGS panel, panel size, and use of RNA sequencing and/or normal-matched sequencing. Additionally, the deﬁnition of actionable varies among physicians and different testing panels.2 Tests with varying features may fall under the umbrella term comprehensive genomic proﬁling (CGP; alternatively, comprehensive molecular proﬁling [CMP]), and the extent to which speciﬁc features enhance patient care in community oncology settings remains ambiguous. Consequently, patients may face limitations with in-network testing options that might not offer a genuinely comprehensive evaluation. Our study assesses how particular features of a CGP panel inﬂuence the detection of clinically relevant or actionable ﬁndings and subsequently affect patient care. Tumor-normal matched sequencing can improve accuracy of somatic variant calling by 28%,3 improve tumor mutational [ascopubs.org/journal/po](ascopubs.org/journal/po | 1)[ |](asco

FAQs

Why is comprehensive genomic profiling (CGP) considered important for cancer treatment?

CGP is advocated to tailor precision-guided therapies for patients with cancer. It helps identify genomic biomarkers linked to FDA-approved treatments.

How did the study assess the impact of CGP panel features?

The study used a pilot pan-cancer cohort receiving NGS-based CGP and an expanded analysis of de-identified patient records. It evaluated potentially actionable findings, including those detected only by advanced features.

Which advanced CGP features contributed to improved detection of actionable findings?

Tumor-normal matching, RNA sequencing, and liquid biopsy reﬂex testing were identified as key features that found actionable alterations not detected by existing in-network NGS options.

Sep 23, 2026

Uploaded by Taylor Morgan